Application
Fig1: Western blot analysis of RAN on human RAN recombinant protein using anti-RAN antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of RAN on HEK293 (1) and RAN-hIgGFc transfected HEK293 (2) cell lysate using anti-RAN antibody at 1/1,000 dilution.
Application
Fig3: Western blot analysis of RAN on different cell lysate using anti-RAN antibody at 1/1,000 dilution. Positive control: Line1: Hela Line2: NIH/3T3 Line3: A431 Line4: C6 Line5: Jurkat Line6: Hela Line7: COS7 Line8: Jurkat
Application
Fig4: ICC staining RAN (green) and Actin filaments (red) in GC-7901 cells. Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig5: ICC staining RAN (green) and Actin filaments (red) in Hela cells. Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig6: ICC staining RANRAN (green) and Actin filaments (red) in HepG2 cells. Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig7: Immunohistochemical analysis of paraffin-embedded human cervical cancer tissue using anti-RAN antibody. Counter stained with hematoxylin.
Application
Fig8: Immunohistochemical analysis of paraffin-embedded human stomach cancer tissue using anti-RAN antibody. Counter stained with hematoxylin.
Application
Fig9: Flow cytometric analysis of Hela cells with RAN antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).